Carlsmed, Inc. Common Stock

NASDAQ:CARL USA Health Information Services
Market Cap
$311.00 Million
Market Cap Rank
#17703 Global
#6686 in USA
Share Price
$11.70
Change (1 day)
+0.00%
52-Week Range
--
All Time High
$16.99
About

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and … Read more

Carlsmed, Inc. Common Stock (CARL) - Net Assets

Latest net assets as of December 2025: $98.87 Million USD

Based on the latest financial reports, Carlsmed, Inc. Common Stock (CARL) has net assets worth $98.87 Million USD as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($130.12 Million) and total liabilities ($31.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $98.87 Million
% of Total Assets 75.98%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

Carlsmed, Inc. Common Stock - Net Assets Trend (2023–2025)

This chart illustrates how Carlsmed, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Carlsmed, Inc. Common Stock (2023–2025)

The table below shows the annual net assets of Carlsmed, Inc. Common Stock from 2023 to 2025.

Year Net Assets Change
2025-12-31 $98.87 Million +239.98%
2024-12-31 $-70.63 Million -53.11%
2023-12-31 $-46.13 Million --

Equity Component Analysis

This analysis shows how different components contribute to Carlsmed, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5389100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components $199.67 Million 201.96%
Total Equity $98.87 Million 100.00%

Carlsmed, Inc. Common Stock Competitors by Market Cap

The table below lists competitors of Carlsmed, Inc. Common Stock ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Carlsmed, Inc. Common Stock's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -70,630,000 to 98,869,000, a change of 169,499,000.
  • Net loss of 30,218,000 reduced equity.
  • New share issuances of 105,384,000 increased equity.
  • Other factors increased equity by 94,333,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-30.22 Million -30.56%
Share Issuances $105.38 Million +106.59%
Other Changes $94.33 Million +95.41%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares Carlsmed, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.68x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2023-12-31 $-10.38 $11.70 x
2024-12-31 $-4.26 $11.70 x
2025-12-31 $6.95 $11.70 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Carlsmed, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -30.56%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -59.82%
  • • Asset Turnover: 0.39x
  • • Equity Multiplier: 1.32x
  • Recent ROE (-30.56%) is below the historical average (-10.19%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2023 0.00% -137.16% 0.98x 0.00x $-14.29 Million
2024 0.00% -89.30% 0.52x 0.00x $-17.19 Million
2025 -30.56% -59.82% 0.39x 1.32x $-40.10 Million

Industry Comparison

This section compares Carlsmed, Inc. Common Stock's net assets metrics with peer companies in the Health Information Services industry.

Industry Context

  • Industry: Health Information Services
  • Average net assets among peers: $79,108,599
  • Average return on equity (ROE) among peers: -247.59%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Carlsmed, Inc. Common Stock (CARL) $98.87 Million 0.00% 0.32x $113.55 Million
Accolade, Inc. (ACCD) $473.79 Million -97.02% 0.91x $448.32 Million
Achiko AG (ACHKF) $-4.58 Million 0.00% 0.00x $314.42K
Ascom Holding AG (ACMLF) $78.70 Million 22.11% 1.51x $152.13 Million
Accelera Innovations Inc (ACNV) $-462.52K 0.00% 0.00x $5.72K
Aclarion Inc (ACON) $-7.08 Million 0.00% 0.00x $1.89 Million
Alternate Health Corp (AHGIF) $1.07 Million -2231.82% 7.94x $6.50K
AI/ML Innovations Inc (AIMLF) $2.09 Million -130.52% 0.72x $6.84 Million
NetraMark Holdings Inc. (AINMF) $-198.56K 0.00% 0.00x $70.13 Million
AMJ Global Technology (AMJT) $-21.78K 0.00% 0.00x $10.99 Million
American Well Corp (AMWL) $247.79 Million -38.62% 0.31x $78.62 Million